Please use this identifier to cite or link to this item: https://observatorio.fm.usp.br/handle/OPI/37086
Title: AHR is a Zika virus host factor and a candidate target for antiviral therapy
Authors: GIOVANNONI, FedericoBOSCH, IrenePOLONIO, Carolina ManganeliTORTI, Maria F.WHEELER, Michael A.LI, ZhaorongROMORINI, LeonardoVARELA, Maria S. RodriguezROTHHAMMER, VeitBARROSO, AndreiaTJON, Emily C.SANMARCO, Liliana M.TAKENAKA, Maisa C.MODARESI, Seyed Mohamad SadeghGUTIERREZ-VAZQUEZ, CristinaZANLUQUI, Nagela GhabdanSANTOS, Nilton Barreto dosMUNHOZ, Carolina DemarchiWANG, ZhongyanDAMONTE, Elsa B.SHERR, DavidGEHRKE, LeePERON, Jean Pierre SchatzmannGARCIA, Cybele C.QUINTANA, Francisco J.
Citation: NATURE NEUROSCIENCE, v.23, n.8, p.939-+, 2020
Abstract: Zika virus (ZIKV) is a flavivirus linked to multiple birth defects including microcephaly, known as congenital ZIKV syndrome. The identification of host factors involved in ZIKV replication may guide efficacious therapeutic interventions. In genome-wide transcriptional studies, we found that ZIKV infection triggers aryl hydrocarbon receptor (AHR) activation. Specifically, ZIKV infection induces kynurenine (Kyn) production, which activates AHR, limiting the production of type I interferons (IFN-I) involved in antiviral immunity. Moreover, ZIKV-triggered AHR activation suppresses intrinsic immunity driven by the promyelocytic leukemia (PML) protein, which limits ZIKV replication. AHR inhibition suppressed the replication of multiple ZIKV strains in vitro and also suppressed replication of the related flavivirus dengue. Finally, AHR inhibition with a nanoparticle-delivered AHR antagonist or an inhibitor developed for human use limited ZIKV replication and ameliorated newborn microcephaly in a murine model. In summary, we identified AHR as a host factor for ZIKV replication and PML protein as a driver of anti-ZIKV intrinsic immunity. Giovannoni et al. report that the aryl hydrocarbon receptor (AHR) is a novel host factor exploited by Zika virus and dengue virus to evade the immune response. AHR is a candidate target for the treatment of Zika virus congenital syndrome and dengue fever.
Appears in Collections:

Artigos e Materiais de Revistas Científicas - FM/Outros
Outros departamentos - FM/Outros

Artigos e Materiais de Revistas Científicas - ODS/03


Files in This Item:
File Description SizeFormat 
art_GIOVANNONI_AHR_is_a_Zika_virus_host_factor_and_2020.PDF.pdf
  Restricted Access
publishedVersion (English)12.59 MBAdobe PDFView/Open Request a copy

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.